Monnet X, Lamia B, Anguel N, Richard C, Bonmarchand G, Teboul J L
Service de Réanimation Médicale, CHU de Bicêtre, Assistance Publique-Hôpitaux de Paris, Université Paris XI, 78 rue du Général Leclerc, 94270, le Kremlin-Bicêtre, France.
Intensive Care Med. 2005 Nov;31(11):1573-6. doi: 10.1007/s00134-005-2792-0. Epub 2005 Sep 21.
Because recombinant human activated protein C (rhAPC) reduces NO production during sepsis, it could improve the vascular tone. We tested whether rhAPC reduces the dose of norepinephrine required to maintain mean arterial pressure (MAP) in septic shock patients.
Retrospective study in intensive care unit of two university hospitals.
Twenty-two septic shock patients with at least two organ failures were retrospectively investigated for MAP and the required dose of norepinephrine before and 24 h after rhAPC administration. A control group of 22 septic shock patients with at least two organ failures who did not receive rhAPC was matched on age, SAPS II, MAP, and norepinephrine dose at the time of the theoretical start of rhAPC.
The MAP remained stable and similar in the two groups (86+/-16 vs. 89+/-9 mmHg at 24 h). The required dose of norepinephrine increased in the control group (+38%, from -41% to +38%) but decreased in the treated group (-33%, from -74% to +11%).
rhAPC rapidly improved the vascular tone in septic shock patients as assessed by a decrease in the norepinephrine dose required to maintain arterial pressure.
由于重组人活化蛋白C(rhAPC)可降低脓毒症期间的一氧化氮生成,故其可能改善血管张力。我们测试了rhAPC是否能降低脓毒性休克患者维持平均动脉压(MAP)所需的去甲肾上腺素剂量。
在两家大学医院的重症监护病房进行的回顾性研究。
对22例至少有两个器官功能衰竭的脓毒性休克患者在给予rhAPC之前及之后24小时的MAP和所需去甲肾上腺素剂量进行回顾性研究。选取22例至少有两个器官功能衰竭且未接受rhAPC的脓毒性休克患者作为对照组,对照组在理论上开始给予rhAPC时的年龄、简化急性生理学评分II(SAPS II)、MAP和去甲肾上腺素剂量与研究组相匹配。
两组患者的MAP均保持稳定且相似(24小时时分别为86±16 mmHg和89±9 mmHg)。对照组所需的去甲肾上腺素剂量增加(从-41%增至+38%,增加了38%),而治疗组所需剂量减少(从-74%降至+11%,减少了33%)。
根据维持动脉压所需去甲肾上腺素剂量的减少来评估,rhAPC可迅速改善脓毒性休克患者的血管张力。